{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T11:06:47Z","timestamp":1779966407120,"version":"3.53.1"},"reference-count":28,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>This study aims to evaluate the short-term outcomes and prognosis and the cardiac safety of pegylated liposomal doxorubicin (PLD)-based neoadjuvant chemotherapy (NAC) compared with epirubicin-based therapy in breast cancer treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In total, 304 patients diagnosed with stages II and III breast cancer were enrolled that included 97 cases treated with PLD and 207 controls treated with epirubicin in NAC. The effectiveness of the antibreast cancer treatment was evaluated using overall survival (OS) and disease-free survival (DFS) metrics, whereas cardiac toxicity was measured through the left ventricular ejection fraction (LVEF) and electrocardiogram (ECG) assessments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The 5-year DFS and OS rates in the PLD group were 84.5% and 88.7% (with 15 recurrences and 11 deaths), respectively, whereas in the control group, these rates were 72.9% and 79.2% (with 56 recurrences and 43 deaths). Regarding cardiac toxicity, there was no significant difference in ECG abnormalities or LVEF decline between the two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The study suggests that PLD-based NAC may provide substantial benefits in terms of DFS and OS, along with a safe cardiac toxicity profile, in patients with stage II\u2013III breast cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cbr.2024.0011","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T12:20:55Z","timestamp":1711023655000},"page":"203-209","source":"Crossref","is-referenced-by-count":1,"title":["The Survival Benefit of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in the Management of Breast Cancer"],"prefix":"10.1177","volume":"41","author":[{"given":"Ruoyang","family":"Li","sequence":"first","affiliation":[{"name":"Breast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Medicine, Fourth Hospital of Hebei Medical University, Shijiazhuang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Huang","sequence":"additional","affiliation":[{"name":"Breast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiao","family":"Li","sequence":"additional","affiliation":[{"name":"Breast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[{"name":"Breast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiqi","family":"Wang","sequence":"additional","affiliation":[{"name":"Breast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxing","family":"Wang","sequence":"additional","affiliation":[{"name":"Breast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3674-1946","authenticated-orcid":false,"given":"Zhenchuan","family":"Song","sequence":"additional","affiliation":[{"name":"Breast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,5,3]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.15.0235"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199300452-00004"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0305-7372(95)90001-2"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0001"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2011.09.006"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1081\/cnv-200032899"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342050-00002"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2016.10.003"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1159\/000498993"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-54387-5"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-015-3415-2"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.2.460"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-011-2108-2"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7156"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.10.8407"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5729389"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature11412"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2014.921727"},{"issue":"9","key":"e_1_3_5_20_2","first-page":"3817","article-title":"Phase II study of neoadjuvant gemcitabine, pegylated liposomal doxorubicin, and docetaxel in locally advanced breast cancer","volume":"30","author":"Artioli G","year":"2010","unstructured":"Artioli G, , Mocellin S, , Borgato L, et al. Phase II study of neoadjuvant gemcitabine, pegylated liposomal doxorubicin, and docetaxel in locally advanced breast cancer. Anticancer Res, 2010; 30(9):3817\u20133821.","journal-title":"Anticancer Res"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e3283043585"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0268"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf284"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.9191"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyy181"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16010124"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22521"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1159\/000500204"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1433-4"}],"container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cbr.2024.0011","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2024.0011","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2024.0011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T10:41:26Z","timestamp":1779964886000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cbr.2024.0011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4,1]]}},"alternative-id":["10.1089\/cbr.2024.0011"],"URL":"https:\/\/doi.org\/10.1089\/cbr.2024.0011","relation":{},"ISSN":["1084-9785","1557-8852"],"issn-type":[{"value":"1084-9785","type":"print"},{"value":"1557-8852","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}